Yüklüyor......
Potential targets for pancreatic cancer immunotherapeutics
Pancreatic adenocarcinoma is the fourth leading cause of cancer death with an overall 5-year survival of less than 5%. As there is ample evidence that pancreatic adenocarcinomas elicit antitumor immune responses, identification of pancreatic cancer-associated antigens has spurred the development of...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3148788/ https://ncbi.nlm.nih.gov/pubmed/21463193 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/imt.11.10 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|